Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Vicore Pharma Holding AB ( (SE:VICO) ) just unveiled an update.
Vicore Pharma Holding AB has announced an increase in its number of shares and votes due to the exercise of warrants in its incentive programs. This development reflects the company’s ongoing efforts to enhance its capital structure and potentially strengthen its market position as it continues to advance its drug candidates.
More about Vicore Pharma Holding AB
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on developing a new class of drugs with disease-modifying potential for respiratory and fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF). Their leading product, buloxibutid (C21), is an oral small molecule angiotensin II type 2 (AT2) receptor agonist, which has received Orphan Drug and Fast Track designation from the FDA and is currently in a Phase 2b trial.
YTD Price Performance: -6.86%
Average Trading Volume: 370,352
Current Market Cap: SEK1.85B
Learn more about VICO stock on TipRanks’ Stock Analysis page.